公开(公告)号：US20160031969A1

公开(公告)日：2016-02-04

申请号：US14775482

申请日：2014-03-13

申请人： AMGEN INC.

发明人： Jeonghoon Sun ,  Jason Charles O'Neill ,  Randal R. Ketchem ,  Randy Ira Hecht ,  Edward J. Belouski ,  Mark Leo Michaels

IPC分类号： C07K14/81

CPC分类号： C07K14/8146 ,  A61K38/00 ,  C12N9/6489

摘要： There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

摘要翻译： 公开了TIMP-3突变蛋白，变体和衍生物，编码它们的核酸，以及制备和使用它们的方法。

公开(公告)号：US11104745B2

公开(公告)日：2021-08-31

申请号：US16062096

申请日：2016-12-14

申请人： AMGEN INC.

发明人： Hailing Hsu ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Michelle Hortter ,  Edward J. Belouski

IPC分类号： C07K16/46 ,  C07K16/24 ,  A61K39/395 ,  C07K16/28 ,  C12N15/10

摘要： The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.

公开(公告)号：US10189890B2

公开(公告)日：2019-01-29

申请号：US14775482

申请日：2014-03-13

申请人： AMGEN INC.

发明人： Jeonghoon Sun ,  Jason Charles O'Neill ,  Randal R. Ketchem ,  Randy Ira Hecht ,  Edward J. Belouski ,  Mark Leo Michaels

IPC分类号： C07K14/435 ,  A61K38/16 ,  C12N15/09 ,  C12N15/11 ,  C12N15/12 ,  C12N15/63 ,  C07K14/81 ,  C12N9/64 ,  A61K38/00

摘要： There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

公开(公告)号：US20160244497A1

公开(公告)日：2016-08-25

申请号：US15007438

申请日：2016-01-27

申请人： Amgen Inc.

发明人： Kenneth W. WALKER ,  Colin V. Gegg, JR. ,  Randy I. Hecht ,  Edward J. Belouski ,  Yue-Sheng Li ,  Mark L. Michaels ,  Jing Xu ,  Murielle Marie Ellison

IPC分类号： C07K14/50 ,  A61K47/48

CPC分类号： C07K14/50 ,  A61K38/00 ,  A61K47/60

摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

摘要翻译： 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。

公开(公告)号：US11919964B2

公开(公告)日：2024-03-05

申请号：US17005202

申请日：2020-08-27

申请人： AMGEN INC.

发明人： Gunasekaran Kannan ,  Ling Liu ,  Edward J. Belouski ,  Cen Xu

IPC分类号： C07K16/28 ,  C07K16/18

CPC分类号： C07K16/2869 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

公开(公告)号：US10934362B2

公开(公告)日：2021-03-02

申请号：US15511176

申请日：2015-09-15

申请人： AMGEN INC.

发明人： Gunasekaran Kannan ,  Ling Liu ,  Edward J. Belouski ,  Cen Xu

IPC分类号： C07K16/28 ,  C07K16/18

摘要： The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

公开(公告)号：US20190085054A1

公开(公告)日：2019-03-21

申请号：US16209239

申请日：2018-12-04

申请人： AMGEN INC.

发明人： Jeonghoon Sun ,  Jason Charles O'Neill ,  Randal R. Ketchem ,  Randy Ira Hecht ,  Edward J. Belouski ,  Mark Leo Michaels

IPC分类号： C07K14/81 ,  C12N9/64 ,  A61K38/00

摘要： There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.